Clarke A. Low, MD, discusses osimertinib (Tagrisso) versus dacomitinib (Vizimpro) in EGFR-mutant non–small cell lung cancer.
Clarke A. Low, MD
Advertisement
Articles by Clarke A. Low, MD
Advertisement
Latest Updated Articles
Dr. Low on Osimertinib Versus Dacomitinib in EGFR-Mutant NSCLCOctober 30th 2019
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient mHSPC
2
FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
3
Subgroup Analyses Confirm Clinically Meaningful Revumenib Responses in AML Across Mutational Profiles
4
Data Support Luspatercept at Maximum-Approved Dose for Transfusion-Dependent Lower-Risk MDS
5